{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:03:24Z","timestamp":1792029804249,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Nature Science Foundation of China","award":["LZ24H050001"],"award-info":[{"award-number":["LZ24H050001"]}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"publisher","award":["82170681"],"award-info":[{"award-number":["82170681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Plan Major Project of Jinhua","award":["2023-3-068"],"award-info":[{"award-number":["2023-3-068"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces renal risks in type 2 diabetic nephropathy, but its use in immunoglobulin nephropathy (IgAN) lacks evidence. This study assessed the safety and efficacy of 6-month finerenone treatment in IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was mainly conducted in three Grade 3A hospitals. Patients diagnosed with IgAN and receiving standard supportive care were included. Participants were divided into the renin\u2013angiotensin system inhibitor (RASI) and RASI\u00a0+\u00a0finerenone groups. The primary outcome was the percentage decrease in protein-to-creatinine ratio (PCR) over 6\u00a0months following the index study visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 178 patients were included in the analysis. PCR was reduced by 45.1% in the RASI\u00a0+\u00a0finerenone group and 32.5% in the RASI group (P\u00a0=\u00a0.013). Compared with 18 patients (20.2%) in the control group, 33 (37.1%) had residual PCR reduced to &amp;lt;0.3\u00a0g\/g. After 6\u00a0months, serum potassium increased by 0.17\u00a0mmol\/L from baseline, with no uncontrollable hyperkalemia (persistent serum potassium &amp;gt;5.5\u00a0mmol\/L despite treatment). In addition, one patient presented with a blood pressure &amp;lt;90\/60\u00a0mmHg without significant clinical symptoms in the RASI\u00a0+\u00a0finerenone group. And eGFR decreased by 1.94\u00a0\u00b1\u00a06.73\u00a0mL\/min\/1.73 m2 from baseline, but not statistically significant. There were no differences in the incidence of adverse events between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Finerenone added to optimized RAS blocker therapy significantly reduced PCR in IgAN patients, and its safety profile was consistent with previous reports, suggesting the need for long-term renal outcome studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT06460987<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf125","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T08:06:33Z","timestamp":1745654793000},"source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study"],"prefix":"10.1093","volume":"18","author":[{"given":"Qiao-Rui","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"Jinhua Municipal Central Hospital Department of Nephrology, , Jinhua ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-7556","authenticated-orcid":false,"given":"Fei","family":"Han","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-6291","authenticated-orcid":false,"given":"Yong-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine and Warshel Institute for Computational Biology, Chinese University of Hong Kong , Shenzhen, Guangdong ,","place":["China"]},{"name":"University of Hong Kong Department of Paediatrics and Adolescent Medicine, , Hong Kong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Lian","family":"Wu","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital, Zhejiang University School of Medicine Department of Pharmacy, , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Center for Regeneration and Aging Medicine, the Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University Department of Nephrology, , Yiwu, Zhejiang ,","place":["China"]},{"name":"Zhejiang-Denmark Joint Laboratory of Regeneration and Aging Medicine , Yiwu, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2025051205271045600_bib1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA Nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025051205271045600_bib2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"Oxford derivation, North American validation and VALIGA Consortia. The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib4","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025051205271045600_bib5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2025051205271045600_bib6","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2025051205271045600_bib7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025051205271045600_bib8","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025051205271045600_bib9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2025051205271045600_bib10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/CLEP.S129785","article-title":"Missing data and multiple imputation in clinical epidemiological research","volume":"9","author":"Pedersen","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2025051205271045600_bib11","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cjca.2020.11.010","article-title":"Missing data in clinical research: a tutorial on multiple imputation","volume":"37","author":"Austin","year":"2021","journal-title":"Can J Cardiol"},{"key":"2025051205271045600_bib12","first-page":"669","article-title":"Advanced statistics: missing data in clinical research\u2014part 2: multiple imputation","volume":"14","author":"Newgard","year":"2007","journal-title":"Acad Emerg Med"},{"key":"2025051205271045600_bib13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025051205271045600_bib14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2025051205271045600_bib15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"2025051205271045600_bib16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025051205271045600_bib17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/eurheartj\/ehac683","article-title":"Prevention of cardiorenal damage: importance of albuminuria","volume":"44","author":"Ruilope","year":"2023","journal-title":"Eur Heart J"},{"key":"2025051205271045600_bib19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025051205271045600_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000489914","article-title":"Add-on effect of angiotensin receptor blockade (Candesartan) on clinical remission in active IgA nephropathy patients treated with steroid pulse therapy and tonsillectomy: a randomized, parallel-group comparison trial","volume":"43","author":"Kohagura","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"2025051205271045600_bib21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"Shimizu","year":"2008","journal-title":"Hypertens Res"},{"key":"2025051205271045600_bib22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025051205271045600_bib24","doi-asserted-by":"publisher","first-page":"e20513","DOI":"10.1097\/MD.0000000000020513","article-title":"Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria","volume":"99","author":"Pei","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025051205271045600_bib25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"2025051205271045600_bib27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2025051205271045600_bib30","doi-asserted-by":"publisher","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025051205271045600_bib31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"2025051205271045600_bib32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025051205271045600_bib33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf125\/63024603\/sfaf125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf125\/63024603\/sfaf125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/5\/sfaf125\/63024603\/sfaf125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:27:18Z","timestamp":1747027638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf125\/8121406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf125","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,28]]},"article-number":"sfaf125"}}